Telix Pharmaceuticals Ltd — Board/Management Information 2019

Feb 17, 2019

==> picture [143 x 79] intentionally omitted <==

Telix appoints Gabriel Liberatore as Group COO

Melbourne (Australia) – 18[th] February 2019 . Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularlytargeted radiation” (“MTR”), today announces the appointment of Mr Gabriel Liberatore as Group Chief Operating Officer.

Mr Liberatore has twenty years’ experience in senior business development and R&D management positions within the Pharmaceutical/ Biotechnology/ Life Science sector, including twelve years at CSL Limited (ASX:CSL), three years at Deloitte (Australia) and Swisse Wellness (HK:112) respectively, and most recently with the PACT Group (ASX:PGH).

Gabriel holds a PhD in Neuroscience from the University of Melbourne, with a post-doctorate at Columbia University and a MBA (Corporate Strategy) from La Trobe University. Gabriel is an Advisory Board member at Swinburne University, a member of the Australian Institute of Company Directors and a member of the Licensing Executives Society of Australia and New Zealand (LESANZ).

Group CEO, Dr Christian Behrenbruch said, “We are very pleased to welcome Gabriel to the Telix Team. His extensive experience in executive-level operational leadership across the pharma and biotech sectors comes at a pivotal time for the Group as we expand global operations and strategic partnerships across all of our programs.”

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact Telix Investor Relations

Dr. Christian Behrenbruch Lisa Wilson Telix Pharmaceuticals Limited In-Site Communications CEO Tel: +1 212 452 2793 Email: chris@telixpharma.com Email: lwilson@insitecony.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the products referred to in this release have obtained a marketing authorization in any jurisdiction.

Page 1